secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001628280-24-023035
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical Q1 record sales $22.7M (+15% YoY); raises 2024 guidance across all metrics
--------------------------------------------------------------------------------

- Q1 net sales $22.7M (record), up 15% YoY; ex-deferred revenue, up 25%. Gross profit $3.1M (+18% YoY).
- Net loss improved to $1.7M from $1.8M YoY; adjusted EBITDA ($0.5M) vs ($1.0M).
- Raised FY2024 guidance: net sales $90-94M (prev $84-88M); gross profit $13-15M; adjusted EBITDA $0.5-1.0M.
- Amended Innovatus loan: rate reduced, maturity extended to Jan 2029; interest-only through Sep 2026.
- New distribution deals with BioNuclear and AMI expected ~$1M annual revenue; new supply agreement with large Mountain West health system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828024023035/0001628280-24-023035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828024023035/rmti-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-023035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer